Dr. Oluseun Alli, MD
Claim this profileNovant Health Heart and Vascular Research Institute
Studies Stroke
Studies Bleeding
6 reported clinical trials
8 drugs studied
Affiliated Hospitals
Clinical Trials Oluseun Alli, MD is currently running
AMPLATZER PFO Occluder
for Patent Foramen Ovale
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
Recruiting1 award N/A1 criteria
PCI vs Medical Management
for Aortic Stenosis
Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management. The potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance. The COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure. The study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR. Complete Revascularization: Staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR. Vs. Medical Therapy Alone: No further revascularization of coronary artery lesions. All patients, regardless of randomized treatment allocation, will receive guideline-directed medical therapy consisting of risk factor modification and use of evidence-based therapies. The COMPLETE TAVR study will help address the current lack of evidence in this area. It will likely impact both the global delivery of health care and the management and clinical outcomes of all patients undergoing TAVR with concomitant CAD.
Recruiting1 award N/A4 criteria
More about Oluseun Alli, MD
Clinical Trial Related6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Oluseun Alli, MD has experience with
- Percutaneous Coronary Intervention (PCI)
- Device
- AMPLATZER™ PFO Occluder
- WATCHMAN FLX LAAC Device
- Non-Vitamin K Oral Anticoagulant
- TriClip Device
Breakdown of trials Oluseun Alli, MD has run
Stroke
Atrial Fibrillation
Aortic Stenosis
Coronary Artery Stenosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Oluseun Alli, MD specialize in?
Oluseun Alli, MD focuses on Stroke and Bleeding. In particular, much of their work with Stroke has involved treating patients, or patients who are undergoing treatment.
Is Oluseun Alli, MD currently recruiting for clinical trials?
Yes, Oluseun Alli, MD is currently recruiting for 3 clinical trials in Charlotte North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Oluseun Alli, MD has studied deeply?
Yes, Oluseun Alli, MD has studied treatments such as Percutaneous Coronary Intervention (PCI), Device, AMPLATZER™ PFO Occluder.
What is the best way to schedule an appointment with Oluseun Alli, MD?
Apply for one of the trials that Oluseun Alli, MD is conducting.
What is the office address of Oluseun Alli, MD?
The office of Oluseun Alli, MD is located at: Novant Health Heart and Vascular Research Institute, Charlotte, North Carolina 28204 United States. This is the address for their practice at the Novant Health Heart and Vascular Research Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.